Bacteriotherapy reintroduces “old friends” in IBD

DOI 参考文献46件
  • Nanki Kosaku
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
  • Naganuma Makoto
    Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan
  • Mizuno Shinta
    Department of Gastroenterology and Hepatology, Saiseikai Central Hospital, Tokyo, Japan
  • Matsuoka Katsuyoshi
    Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan
  • Kanai Takanori
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

この論文をさがす

抄録

Various strains of microorganisms inhabit the human gut and greatly impact human health. Recent advances in next-generation sequencing techniques revealed a correlation between alterations to the composition of gastrointestinal microbiota: called dysbiosis, and inflammatory bowel disease (IBD), a chronic inflammatory intestinal disorder comprising ulcerative colitis (UC) and Crohn’s disease (CD). These alterations are thus suspected to be among the causes of IBD. Significant lifestyle and environmental changes in modern developed countries may be responsible for the altered gastrointestinal microbiota, and may have greatly contributed to the rapid rise of IBD in the modern era. To date, many trials attempted to treat IBD by restoring altered microbiota using such methods as probiotics and fecal microbiota transplantation (FMT). Currently, more sophisticated and convenient methods of FMT are being devised. The focus is now on FMT, which is expected to be the new direction of IBD therapy.

収録刊行物

参考文献 (46)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ